U NOVARTIS

Novartis India Limited Registered Office: Inspire BKC Part of 601 & 701 Bandra Kurla Complex Bandra (East) Mumbai – 400 051 Maharashtra, India Tel +91 22 50243000 Fax +91 22 50243010 Email: india.investors@novartis.com CIN No. L24200MH1947PLC006104 Website: www.novartis.in

June 29, 2021

To, The Secretary BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai - 400 001

Scrip code: 500672

Sub.: Annual Secretarial Compliance Report for the Financial Year ended March 31, 2021

Dear Sir/ Madam,

Pursuant to Regulation 24A of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Annual Secretarial Compliance Report of the Company issued by Mr. K. G. Saraf, Practicing Company Secretary for the financial year 2020-21.

You are requested to kindly take the above information on record.

Thanking You.

Yours sincerely,

For Novartis India Limited

Trivikram Guda Company Secretary & Compliance Officer

Encl.: As above

SARAF & ASSOCIATES

COMPANY SECRETARIES

www.sarafandassociates.com

423, Hind Rajasthan Building, 95, Dadasaheb Phalke Road, Dadar (C.Rly.), Mumbai - 400 014. (022) 2413 0371 / 2415 3887 (2) +91 98203 20072 (2) kamalax_saraf@hotmail.com

Secretarial Compliance Report of Novartis India Limited For the Financial Year Ended 31st March 2021 (Pursuant to SEBI- CIR/CFD/CMD/1/27/2019 Dated February 8, 2019)

I Mr. **K.G. Saraf**, Practicing Company Secretary (FCS No. 1596, Certificate of Practice No. 642) have examined:

- (a) all the documents and records made available to us and explanation provided by NOVARTIS INDIA LIMITED ("the listed entity"),
- (b) the filings/ submissions made by the listed entity to the stock exchanges,
- (c) website of the listed entity,

(d) any other document/ filing, as may be relevant, which has been relied upon to make this certification,

for the year ended 31st March 2021 ("Review Period") in respect of compliance with the provisions of:

- (a) the Securities and Exchange Board of India Act, 1992 ("SEBI Act") and the Regulations, circulars, guidelines issued thereunder; and
- (b) the Securities Contracts (Regulation) Act, 1956 ("SCRA"), rules made thereunder and the Regulations, circulars, guidelines issued thereunder by the Securities and Exchange Board of India ("SEBI");

The specific Regulations, whose provisions and the circulars/ guidelines issued thereunder, have been examined, include:-

- (a) Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
- (b) Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; (Not applicable for the period under review)
- (c) Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
- (d) Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; (Not applicable for the period under review)
- (e) Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; (Not applicable for the period under review)

Secretarial Compliance Report – Novartis India Limited 2021

- (f) Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; (Not applicable for the period under review)
- (g) Securities and Exchange Board of India (Issue and Listing of Non-Convertible and Redeemable Preference Shares) Regulations,2013; (*Not applicable for the period under review*)
- (h) Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
- (i) The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulations, 1993 regarding the Companies Act and dealing with client;
- (j) The Securities and Exchange Board of India (Depositories and Participant) Regulations, 2018;

and Circulars / Guidelines issued thereunder.

and based on the above examination, I hereby report that, during the Review Period:

(a) The listed entity has complied with the provisions of the above Regulations and circulars/ guidelines issued thereunder, except in respect of matters specified below :-

Sr. No	Compliance Requirement (Regulations/ circulars / guidelines including specific clause)	Deviations	Observations/Remarks of the Practicing Company Secretary
01	 Reg. 30(2) of Listing Obligations and Disclosure Requirements Regulations, 2015. Events specified in Para A of Part A of Schedule III are deemed to be material events and listed entity shall make disclosure of such events. Point 4 of Para A of Part A of Schedule III: The listed entity shall disclose to the Exchange(s), within 30 minutes of the closure of the meeting 	Outcome of the meeting of the Board of Directors held on June 19, 2020 was intimated to BSE with a delay of 50 minutes. End Time: 02.05 PM BSE : 03.25 PM	

Secretarial Compliance Report – Novartis India Limited 2021

- (b) The listed entity has maintained proper records under the provisions of the above Regulations and circulars/ guidelines issued thereunder insofar as it appears from my examination of those records.
- (c) The following are the details of actions taken against the listed entity/ its promoters/ directors/ material subsidiaries either by SEBI or by Stock Exchanges (including under the Standard Operating Procedures issued by SEBI through various circulars) under the aforesaid Acts/ Regulations and circulars/ guidelines issued thereunder:

Sr.No	Action taken by	Details of Violation	Details of action taken E.g. fines, warning letter, debarment, etc.	Observations/ remarks of the Practicing Company Secretary, if any			
Not Applicable							

(d) The listed entity has taken the following actions to comply with the observations made in previous reports:

Sr.No	Observations of the Practicing Company Secretary in the previous reports	Observations made in the secretarial compliance report for the year ended 2019-20	Actions taken by the listed entity, if any	Comments of the Practicing Company Secretary on the actions taken by the listed entity		
Not Applicable						

For Saraf & Associates Practising Company Secretaries

KAMALAX Digitally signed by KAMALAX GANAPAYYA SARAF GANAPAYYA SARAF tots: 2021.06.17 22:36:17 +05'30' Place : Mumbai Date : 17.06.2021 UDIN : F001596C000480272

K.G. SARAF Proprietor FCS: 1596 | CP: 642 FRN. S1988MH004801 PR. 1003/2020

3 | Saraf and Associates (Company Secretaries)